Latigo Biotherapeutics, Inc. (NASDAQ:LTGO – Get Free Report)’s stock price fell 8.9% during trading on Thursday. The company traded as low as $12.20 and last traded at $12.32. Approximately 28,893 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 293,849 shares. The stock had previously closed at $13.52.
Wall Street Analyst Weigh In
Several analysts recently weighed in on the company. Jefferies Financial Group began coverage on Latigo Biotherapeutics in a report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 price objective for the company. Weiss Ratings assumed coverage on Latigo Biotherapeutics in a report on Tuesday, November 3rd. They set a “sell (e-)” rating on the stock. Guggenheim started coverage on Latigo Biotherapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 target price for the company. Wall Street Zen upgraded Latigo Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Leerink Partners initiated coverage on Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set an “outperform” rating and a $36.00 price target on the stock. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $52.25.
Check Out Our Latest Analysis on Latigo Biotherapeutics
Latigo Biotherapeutics Trading Down 6.1%
The stock has a fifty day moving average price of $17.39. The firm has a market capitalization of $841.35 million and a PE ratio of -0.24.
Latigo Biotherapeutics (NASDAQ:LTGO – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.55) EPS for the quarter.
Latigo Biotherapeutics Company Profile
Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid medicines for pain. Its research focuses on voltage-gated sodium channels, which play a role in transmitting pain signals. The company’s pipeline includes LTG-001, an oral, selective Nav1.8 inhibitor being developed for acute pain, along with additional investigational programs targeting pain conditions. Latigo’s work is aimed at providing alternatives to opioid-based pain treatment. Its product candidates are investigational and have not been established as safe or effective for any use.
Featured Articles
- Five stocks we like better than Latigo Biotherapeutics
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
- 3 Pharmaceutical Stocks That Offer Safety and Growth
- If Japan’s Stock Market Rally Returns, These 3 ETFs Could Benefit
- CoreWeave’s Backlog Is Surging—Can the Stock Follow?
Receive News & Ratings for Latigo Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Latigo Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
